BioDiem secures Japanese patent for BDM-I


By Dylan Bushell-Embling
Friday, 24 May, 2013

BioDiem (ASX:BDM) has expanded its IP protection, securing another Japanese patent for antimicrobial compound BDM-I.

The new patent covers BDM-I as a treatment for malaria and the STD trichomoniasis - both protozoic infections.

BioDiem has already secured similar patents in Europe and the US, and also has patents across all three markets covering BDM-I’s treatment of vulvovaginitis infections caused by thrush, gonorrhoea and chlamydia.

“This latest protozoal patent, coupled with our previous vulvovaginitis patent in key markets, means we now have a comprehensive intellectual property set for the treatment of common female genital health complaints,” BioDiem CEO Julie Phillips said.

BioDiem also has BDM-I patents in Canada, China and Singapore. The company has separately licensed hepatitis B and D vaccine technology from the University of Canberra.

The company is evaluating BDM-I against a range of additional targets, including pneumocystosis, fungal infections and tuberculosis, and the parasitic worms that cause schistosomiasis.

BioDiem shares were trading 11.11% higher at $0.03 as of around 2 pm on Thursday.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd